Free Trial
NASDAQ:FEMY

Femasys 5/9/2024 Earnings Report

Femasys logo
$0.93 +0.01 (+0.98%)
As of 09:42 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Femasys EPS Results

Actual EPS
-$0.17
Consensus EPS
-$0.22
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A

Femasys Revenue Results

Actual Revenue
$0.27 million
Expected Revenue
$0.30 million
Beat/Miss
Missed by -$30.00 thousand
YoY Revenue Growth
N/A

Femasys Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Femasys' next earnings date is estimated for Thursday, August 14, 2025, based on past reporting schedules.

Conference Call Resources

Femasys Earnings Headlines

Banks aren’t ready for this altcoin—are you?
The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket change.
See More Femasys Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Femasys? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Femasys and other key companies, straight to your email.

About Femasys

Femasys (NASDAQ:FEMY), Inc. is a medical device company dedicated to the design, development and commercialization of minimally invasive diagnostic and therapeutic products for women’s reproductive health. Headquartered in Irvine, California, the company is listed on the NASDAQ under the ticker FEMY and focuses on single‐use catheter technologies that enhance procedure accuracy and patient comfort in fertility care.

Its flagship offerings include the FemVue™ catheter system for non‐radiation fallopian tube patency assessment and the FEMME™ embryo transfer catheter, both engineered with proprietary designs and radiopaque markers. These devices address key challenges in assisted reproductive technology by streamlining workflows, reducing patient discomfort and improving clinical outcomes in infertility clinics and hospitals.

Founded in 2012, Femasys serves markets across North America, Europe, Asia-Pacific and select emerging regions. The company has secured CE Mark approval in Europe and is actively pursuing regulatory clearances in the United States and China. Femasys leverages a combination of direct sales and distributor partnerships to expand its global footprint in the rapidly growing fertility device market.

Under the guidance of an experienced executive team, Femasys is advancing a pipeline of next‐generation catheter systems for enhanced uterine and tubal imaging. The company’s board of directors brings deep expertise in healthcare innovation, regulatory strategy and commercial expansion, positioning Femasys to broaden its product portfolio and scale operations worldwide.

View Femasys Profile

More Earnings Resources from MarketBeat